MorphoSys AG said that it expects revenue to grow to between €73 and €77 million this year from €62 million in 2007 on continued demand for antibodies from its proprietary Human Combinatorial Antibody Library (HuCAL). Operating profit is expected to be in a range of €9 to €11 million, compared with €7 million in 2007.
